Recent advances have solidified our understanding that psoriasis is an important systemic inflammatory disease. Specifically, characterization of the inflammatory cells and the cytokine milieu, as well as an appreciation of increased cardiovascular risk factors, vascular disease, and mortality, has been profound. In this issue of the Archives, Love and colleagues remind us of the presence of these important cardiovascular risk factors, some of which cluster as the so-called metabolic syndrome. They estimate that nearly 2.7 million adults with psoriasis in the United States have the metabolic syndrome, representing a unique challenge and an opportunity.
Shelling ML, Kirsner RS. Lack of Appropriate Screening for the Metabolic Syndrome in Patients With Psoriasis Risks Underrecognition and Undertreatment of Important ComorbiditiesComment on “Prevalence of the Metabolic Syndrome in Psoriasis”. Arch Dermatol. 2011;147(4):424-425. doi:10.1001/archdermatol.2011.55